↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Krones C) "

Sökning: WFRF:(Krones C)

Resultat 1-4 av 4

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Pinkney, T, et al. (författare) The relationship between method of anastomosis and anastomotic failure after right hemicolectomy and ileo-caecal resection: an international snapshot audit 2017 Ingår i: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. - : Wiley. - 1463-1318 .- 1462-8910. ; 19:8, s. O296-O311 Tidskriftsartikel (refereegranskat)
2.	Stickel, F, et al. (författare) Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis 2014 Ingår i: Human molecular genetics. - : Oxford University Press (OUP). - 1460-2083 .- 0964-6906. ; 23:14, s. 3883-3890 Tidskriftsartikel (refereegranskat)
3.	Baghdasaryan, A., et al. (författare) Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis 2016 Ingår i: Journal of Hepatology. - : Elsevier BV. - 0168-8278. ; 64:3, s. 674-681 Tidskriftsartikel (refereegranskat)abstract Background and Aims: Approximately 95% of bile acids (BAs) excreted into bile are reabsorbed in the gut and circulate back to the liver for further biliary secretion. Therefore, pharmacological inhibition of the ileal apical sodium-dependent BA transporter (ASBT/SLC10A2) may protect against BA-mediated cholestatic liver and bile duct injury. Methods: Eight week old Mdr2(-/-) (Abcb4(-/-)) mice (model of cholestatic liver injury and sclerosing cholangitis) received either a diet supplemented with A4250 (0.01% w/w) - a highly potent and selective ASBT inhibitor - or a chow diet. Liver injury was assessed biochemically and histologically after 4 weeks of A4250 treatment. Expression profiles of genes involved in BA homeostasis, inflammation and fibrosis were assessed via RT-PCR from liver and ileum homogenates. Intestinal inflammation was assessed by RNA expression profiling and immunohistochemistry. Bile flow and composition, as well as biliary and fecal BA profiles were analyzed after 1 week of ASBT inhibitor feeding. Results: A4250 improved sclerosing cholangitis in Mdr2(-/-) mice and significantly reduced serum alanine aminotransferase, alkaline phosphatase and BAs levels, hepatic expression of proinflammatory (Tnf-alpha, Vcam1, Mcp-1) and pro-fibrogenic (Col1a1, Col1a2) genes and bile duct proliferation (mRNA and immunohistochemistry for cytokeratin 19 (CK19)). Furthermore, A4250 significantly reduced bile flow and biliary BA output, which correlated with reduced Bsep transcription, while Ntcp and Cyp7a1 were induced. Importantly A4250 significantly reduced biliary BA secretion but preserved HCO3- and biliary phospholipid secretion resulting in an increased HCO3-/BA and PL/BA ratio. In addition, A4250 profoundly increased fecal BA excretion without causing diarrhea and altered BA pool composition, resulting in diminished concentrations of primary BAs tauro-beta-muricholic acid and taurocholic acid. Conclusions: Pharmacological ASBT inhibition attenuates cholestatic liver and bile duct injury by reducing biliary BA concentrations in mice. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
4.	Fickert, P, et al. (författare) Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice 2013 Ingår i: Hepatology (Baltimore, Md.). - : Ovid Technologies (Wolters Kluwer Health). - 1527-3350 .- 0270-9139. ; 58:6, s. 2056-2069 Tidskriftsartikel (refereegranskat)

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-4 av 4

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (4)

Typ av innehåll: refereegranskat (4)

Författare/redaktör: De Castro, S. (1); Meyer, J. (1); Rossi, E. (1); Sanchez, J. (1); Wang, X. (1); Lange, C. (1); visa fler...; Davies, E. (1); Pal, A. (1); Alonso, J. (1); Abraham-Nordling, M (1); Boyle, K (1); Fearnhead, N (1); Garcia-Granero, E (1); Golda, T (1); Hompes, R (1); Kapur, S (1); Kumar, S (1); Laurberg, S (1); Mikalauskas, S (1); Rocha, R (1); Vierimaa, M (1); Keller, M. (1); Martin, S. (1); Johnson, M. (1); Manca, G. (1); Williams, G. (1); Baghdasaryan, A. (1); Robertson, A. (1); Perry, R (1); Agarwal, T (1); Rasmussen, S (1); Evans, M. (1); Garcia, J. (1); Macdonald, E. (1); Patel, P. (1); Khan, A. (1); Hunt, L (1); Williams, M (1); Alam, N (1); Lozano, R (1); Pereira, J (1); Watson, A (1); Hussain, A (1); Morris, C (1); Evans, J. (1); Knops, S. (1); Sharma, A (1); Barker, J (1); Marschall, Hanns-Ulr ... (1); Yamamoto, T. (1); visa färre...

Lärosäte: Karolinska Institutet (3); Göteborgs universitet (1); Uppsala universitet (1)

Språk: Engelska (4)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy